US 11608354
Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease
granted A61PA61P1/00A61P1/04
Quick answer
US patent 11608354 (Prodrugs of a JAK inhibitor compound for treatment of gastrointestinal inflammatory disease) held by Theravance Biopharma R&D IP, LLC expires Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Theravance Biopharma R&D IP, LLC
- Grant date
- Tue Mar 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 11
- CPC classes
- A61P, A61P1/00, A61P1/04, A61P29/00